(thirdQuint)Naxitamab for Neuroblastoma With Osteomedullary Disease.

 Each patient will receive treatment for up to 93 weeks following the first hu3F8 administration and remain in the trial for 101 weeks.

 After the end of trial visit, each patient will enter a long-term follow-up where they will be monitored for up to 5 years after first treatment cycle.

 Each investigational cycle is started with 5 days, days -4 to 0, of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) administered at 250 mu g/m2/day in advance of the start of hu3F8 administration.

 GM-CSF is thereafter administered at 500 mu g/m2/day on days 1 to 5.

 As standard treatment, hu3F8 is administered at 3 mg/kg/day on days 1, 3, and 5, totalling 9 mg/kg per cycle.

 The first 5 cycles are repeated every 4 weeks up to week 21 and after that the frequency decreases to every 8 weeks through a total of 93 weeks.

 End of treatment will take place around 8 weeks after the last cycle and thereafter long-term follow-up will continue.

.

 Naxitamab for Neuroblastoma With Osteomedullary Disease@highlight

Children and adults diagnosed with high risk neuroblastoma and refractory osteomedullary disease will be treated for up to 93 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF).

 Participants will be followed for up to five years after first dose.

 Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2